CPDC Announces Appointment of Bruno Paquin as Permanent CEO prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published: Feb 24, 2021
HAMILTON, ON, Feb. 24, 2021 /PRNewswire/ - The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [
18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that targets Prostate Specific Membrane Antigen (PSMA), a protein that is overexpressed in prostate cancer.
Prostate cancer is the most common malignancy in Canadian men, accounting for over 23,000 new cases per year and 4,000 deaths annually. Men with recurrent or persistent prostate cancer have poor outcomes, and there is an unmet need to accurately define the location and overall spread of disease in this population to help plan effective treatment.
CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.